Skip to main content

Advertisement

Table 3 Risk factors for AIDS incidence during the follow-up among patients newly diagnosed with HIV infection

From: AIDS incidence trends at presentation and during follow-up among HIV-at-risk populations: a 15-year nationwide cohort study in Taiwan

  Number of patients, n Number of AIDS, n % Univariable analysis, crude HR (95% CI) Multivariable analysis, adjusted HR (95% CI)
Age group
  ≤ 30 9826 843 8.6 1.0 (Reference) 1.0 (Reference)
 31–40 5312 442 8.3 0.97 (0.87–1.09) 1.17 (1.04–1.32)**
 41–50 2028 227 11.2 1.35 (1.16–1.56)*** 1.68 (1.44–1.96)***
  ≥ 51 737 127 17.2 2.19 (1.82–2.64)*** 2.36 (1.90–2.92)***
Sex
 Female 1302 96 7.4 1.0 (Reference) 1.0 (Reference)
 Male 16,601 1543 9.3 1.26 (1.03–1.55)* 1.16 (0.93–1.44)
HIV-transmission route
 PWID 6435 361 5.6 1.0 (Reference) 1.0 (Reference)
 Bisexual contact 1322 148 11.2 2.05 (1.69–2.48)*** 2.62 (2.11–3.24)***
 Heterosexual contact 2496 312 12.5 2.33 (2.00–2.71)*** 2.79 (2.35–3.31)***
 Homosexual contact 7602 808 10.6 1.94 (1.71–2.19)*** 2.58 (2.19–3.03)***
 Othera 48 10 20.8 4.92 (2.62–9.22)*** 4.90 (2.58–9.31)***
Urbanization
 Rural 6038 557 9.2 1.0 (Reference) 1.0 (Reference)
 Urban 11,865 1082 9.1 0.99 (0.89–1.09) 0.93 (0.83–1.04)
Income level, n (%)
 Low 11,323 950 8.4 1.0 (Reference) 1.0 (Reference)
 Intermediate 4833 508 10.5 1.26 (1.13–1.41)*** 0.97 (0.86–1.08)
 High 1747 181 10.4 1.24 (1.06–1.46)** 0.84 (0.71–0.99)*
Cohort period
 Period 1 957 43 4.5 1.0 (Reference) 1.0 (Reference)
 Period 2 1777 68 3.8 0.85 (0.58–1.24) 0.82 (0.56–1.21)
 Period 3 6890 559 8.1 1.84 (1.35–2.51)*** 3.32 (2.42–4.56)***
 Period 4 3976 458 11.5 2.67 (1.95–3.65)*** 3.53 (2.57–4.84)***
 Period 5 4303 511 11.9 2.76 (2.02–3.76)*** 3.04 (2.22–4.17)***
Region
 Taipei area 6166 526 8.5 1.0 (Reference) 1.0 (Reference)
 Northern Taiwan 2581 279 10.8 1.28 (1.11–1.48)*** 1.41 (1.22–1.64)***
 Central Taiwan 3209 275 8.6 1.00 (0.87–1.16) 1.06 (0.91–1.23)
 Southern Taiwan 2137 197 9.2 1.09 (0.92–1.28) 1.17 (0.98–1.38)
 Kaoping area 3466 324 9.4 1.10 (0.96–1.27) 1.14 (0.98–1.32)
 Eastern Taiwan 344 38 11.1 1.30 (0.94–1.81) 1.16 (0.82–1.64)
DM
 No 17,556 1590 9.1 1.0 (Reference) 1.0 (Reference)
 Yes 347 49 14.1 1.69 (1.27–2.25)*** 1.08 (0.79–1.46)
CKD
 No 17,717 1610 9.1 1.0 (Reference) 1.0 (Reference)
 Yes 186 29 15.6 1.89 (1.31–2.73)*** 1.49 (1.02–2.17)*
CHF
 No 17,861 1630 9.1 1.0 (Reference) 1.0 (Reference)
 Yes 42 9 21.4 2.82 (1.46–5.43)** 1.81 (0.92–3.58)
COPD
 No 17,626 1604 9.1 1.0 (Reference) 1.0 (Reference)
 Yes 277 35 12.6 1.47 (1.05–2.05)* 1.00 (0.71–1.41)
Cancer
 No 16,788 1506 9.0 1.0 (Reference) 1.0 (Reference)
 Yes 1115 133 11.9 1.38 (1.15–1.64)*** 1.09 (0.91–1.31)
CVD
 No 17,765 1622 9.1 1.0 (Reference) 1.0 (Reference)
 Yes 138 17 12.3 1.47 (0.91–2.36) 1.01 (0.62–1.65)
HAART during follow-up period
 No 5173 120 2.3 1.0 (Reference) 1.0 (Reference)
 Yes 12,730 1519 11.9 1.43 (1.29–1.59)*** 1.29 (1.15–1.44)***
  1. Note. * P < 0.05; ** P < 0.001; *** P < 0.001
  2. Abbreviation: AIDS acquired immunodeficiency syndrome, CHF chronic heart failure, CI confidence intervals, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, DM diabetes mellitus, HAART highly active antiretroviral therapy, HR hazard ratios, PWID people who injected drugs
  3. aIncludes those exposed to blood products, mother-to-child transmission, and unknown exposures